CKPT, Checkpoint Therapeutics and Wainwright
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...
D. Boral Capital lowered the firm’s price target on Checkpoint Therapeutics (CKPT) to $4.80 from $9 and keeps a Buy rating on the shares. The ...
(Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire ...
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT)’s sale to Sun Pharmaceutical Industries Limited for $4.10 per share and a contingent value right for up to $0.70 per share on achievement of a milestone.
On March 9, 2023, Checkpoint announced the deal with Sun Pharma, under which shareholders will receive $4.10 per share in cash (or a total of $355 million). if cosibelimab receives EU approval within ...
CKPT's pipeline includes cosibelimab, olafertinib for EGFR-mutated NSCLC, and CK-103, but their financial health is precarious with significant cash burn. Despite having an approved drug ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results